confirms this hypothesis and showed that IFN-β combined with gemcitabine was able to induce synergistically anti-tumour effects even in the pancreatic cancer cells with low IFN receptor expression [22]. This evidence concerns the gene IFNB1 and familial pancreatic carcinoma.